Cardiac issues of noncardiac drugs: The rising story of avastin in age-related macular degeneration

Ophthalmologica

Volumn 231, Issue 2, 2014, Pages 75-79

  Cruess, Alan F ^a   Giacomantonio, Nicholas ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Intravitreal anti VEGF therapies; Safety; Wet age related macular degeneration

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN;

BACTERIAL INFECTION; BLINDNESS; BLOOD RETINA BARRIER; CANCER PATIENT; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PACKAGING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENDOPHTHALMITIS; EYE INFLAMMATION; FOLLOW UP; HUMAN; MEDICARE; NONHUMAN; OFF LABEL DRUG USE; POSTMARKETING SURVEILLANCE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT; AGE RELATED MACULAR DEGENERATION; AGING; ARTERY THROMBOSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; FOOD SAFETY; HEART INFARCTION; HYPERTENSION; SOCIAL STATUS; WET MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD-RETINAL BARRIER; HEART DISEASES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84893029228     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000355569     Document Type: Review

References (31)

1. Lee S, Chen TT, Barber CL, et al: Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007; 130: 691-703
2. Foundations for a Canadian Vision Health Strategy: Towards Preventing Avoidable Blindness and Promoting Vision Health. http://www.visionhealth.ca/ projects/documents/ Foundations-For-A-Canadian-Vision-Health-Strategy.pdf (accessed March 3, 2012
3. Ambati J, Ambati BK, Yoo SH, Lanchulev S, Adamis AP: Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003; 48: 257-293
4. Chen HX, Cleck JN: Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6: 465-477
5. Boyer DS, Heier JS, Brown DM, et al: A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009; 116: 1731-1739
6. Bakri SJ, Snyder MR, Reid JM, et al: Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855-859
7. Barros-Pereira R, Costa R, Falcao M, et al: Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab or ranibizumab in the treatment of neovascular age-related macular degeneration. Association for Research in Vision and Ophthalmology Annual Meeting, May 2011
8. Carneiro AM, Costa R, Falcão MS, et al: Vascular endothelial growth factor plasma levels before and after treatment of neovascular agerelated macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol 2012; 90:e25-e30
9. IVAN Study Investigators: Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. Ophthalmology 2012; 119: 1399-1411
10. Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Bahcecioglu H: The effect of intravitreal bevacizumab (Avastin) administration on systemic hypertension. Eye (Lond) 2009; 23: 1714-1718
11. Curtis LH, Hammill BG, Schulman KA, Cousins SW: Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010; 128: 1273-1279
12. Gower EW, Cassard C, Chu L, Varma R, Klein R: Adverse event rates following intravitreal injection of Avastin or Lucentis for treating age-related macular degeneration (abstract 6644). Association for Research in Vision and Ophthalmology Annual Meeting, May 2011
13. Carneiro AM, Barthelmes D, Falcão MS, et al: Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica 2011; 225: 211-221
14. CATT Research Group: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908
15. Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group: Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 2012; 119: 1388-1398
16. Ferrara N, Damico L, Shams N, Lowman H, Kim R: Development of ranibizumab, an antivascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26: 859-870
17. Kim H, Robinson SB, Csaky KG: FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 2009; 15: 2803-2812
18. Holland S, Ma P, Maberley D, et al: Outbreak of acute intraocular inflammation after bevacizumab intravitreal injection: An epidemiological investigation (abstract 1444). 72nd Annual Meeting of the Canadian Ophthalmological Society, Toronto, June 22, 2009
19. Georgopoulos M, Polak K, Prager F: Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009; 93: 457-462
20. Health Canada: Reports of eye inflammation, endophthalmitis, and toxic anterior segment syndrome (TASS) following off-label intravitreal use of Avastin ® (bevacizumab) -for health professionals. http://www.hc-sc.gc.ca/ dhp-mps/medeff/advisories-Avis/prof/ -2008/avastin-4-hpc-cps-eng.php (accessed March 3, 2012
21. Avastin Product Monograph, September 2011
22. Pollack A: Avastin injections are reported to cause blindness. The New York Times, August 30, 2011. http://www.nytimes. com/2011/08/31/health/31drug. html (accessed March 3, 2012
23. Health Canada: Reports of severe infectious endophthalmitis leading to blindness following use of Avastin ® (bevacizumab) when repackaged for unauthorized intravitreal injection. http://www.hc-sc.gc.ca/dhp-mps/ medeff/advisories-Avis/prof/-2011/avastin- 8-hpc-cps-eng.php (accessed March 3, 2012
24. Avastin ® Summary of Product Characteristics. September 6, 2012. http://www.ema.europa. eu/docs/en-GB/document-library/ EPAR-Product-Information/ human/ 000582/WC500029271.pdf (accessed December 17, 2012
25. Off-label intravitreal use of the medicinal product Avastin ® (bevacizumab): Modifications of the Summary of Product Characteristics introduced by the CHMP (committee for Medicinal Products for Human Use) of the European Medicines Agency (EMA). October 3, 2012. http://www.agenziafarmaco. gov.it/it/content/uso-intravitreale-labeldella-specialit%C3%A0- medicinaleavastin% C2%AE-bevacizumab-modifichedel-riass (official English translation by the Ordre des Traducteurs, Terminologues et Interprètes Agrégés du Québec
26. Tan JS, Mitchell P, Smith W, Wang JJ: Cardiovascular risk factors and the long-Term incidence of age-related macular degeneration: The Blue Mountains Eye Study. Ophthalmology 2007; 114: 1143-1150
27. Hogg RE, Woodside JV, Gilchrist SE, Graydon R, Fletcher AE, Chan W, Knox A, Cartmill B, Chakravarthy U: Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization. Ophthalmology 2008; 115: 1046-1052
28. Hong T, Tan AG, Mitchell P, Wang JJ: A review and meta-Analysis of the association between C-reactive protein and age-related macular degeneration. Surv Ophthalmol 2011; 56: 184-194
29. Duan Y, Mo J, Klein R: Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans. Ophthalmology 2007; 14: 732-737
30. Wong TY, Tikellis G, Sun C: Age-related macular degeneration and risk of coronary heart disease: The Atherosclerosis Risk in Communities Study. Ophthalmology 2007; 114: 86-91
31. Lee DS, Chiu M, Manuel DG, et al: Trends in risk factors for cardiovascular disease in Canada: Temporal, socio-demographic and geographic factors. CMAJ 2009; 181:E55-E66